Literature DB >> 12378527

Comprehensive allelotyping of well-differentiated human hepatocellular carcinoma with semiquantitative determination of chromosomal gain or loss.

Takafumi Nishimura1, Naoshi Nishida, Teruaki Itoh, Masato Kuno, Mutsuko Minata, Toshiki Komeda, Yoshihiro Fukuda, Iwao Ikai, Yoshio Yamaoka, Kazuwa Nakao.   

Abstract

Allelic imbalance (AI), which represents certain chromosomal gains or losses, has been described in human hepatocellular carcinoma (HCC), but the impact of AI on the early stage of hepatocarcinogenesis has not been fully clarified. Moreover, no previous allelotype studies have identified the difference in chromosomal gain and loss that results in AI. To resolve these problems, we examined 18 well-differentiated HCCs with comprehensive allelotyping by using 400 microsatellite markers with semiquantitative assessment of chromosomal gain or loss. To detect allelic gain effectively, the cutoff value of the allelic imbalance index was set at 0.70. Each allele showing imbalance was subjected to multiplex PCR with use of a retained allele as an internal control to determine whether the imbalance was the result of chromosomal gain or loss. High frequencies of chromosomal gains were detected at 1q (D1S196-D1S2785, 56%), 5q (D5S647-D5S2027, 44%), 6p (6pter-D6S309, 33%), 7 (7pter-D7S657, 22%), and 8q (D8S514-qter, 44%), whereas chromosomal losses were frequently observed at 1p (1pter-D1S234, 22%), 8p (8pter-D8S549, 44%), and 17p (17pter-D17S921, 28%). The extent of overall chromosomal aberration was closely related to the maximum tumor diameter (P = 0.002) and the presence of hepatitis B surface antigen (P = 0.03). Recurrent chromosomal losses at 1p and 8p and gains at 1q and 8q, even in HCCs with a minimal extent of aberrant chromosomes, indicate that these alterations were critical in the early stage of hepatocarcinogenesis. On the other hand, deletions of 13q and 16q were infrequent and were seen only in the most aberrant cases, which suggested that these were late events. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378527     DOI: 10.1002/gcc.10126

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  5 in total

Review 1.  Chromosome 1q21 amplification and oncogenes in hepatocellular carcinoma.

Authors:  Leilei Chen; Tim Hon Man Chan; Xin-yuan Guan
Journal:  Acta Pharmacol Sin       Date:  2010-08-02       Impact factor: 6.150

2.  Evaluation of 1p36 markers and clinical outcome in a skull base chordoma study.

Authors:  Mauro Longoni; Francesca Orzan; Michela Stroppi; Nicola Boari; Pietro Mortini; Paola Riva
Journal:  Neuro Oncol       Date:  2007-12-19       Impact factor: 12.300

3.  Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.

Authors:  Naoshi Nishida; Masatoshi Kudo; Takafumi Nishimura; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naosuke Yokomichi; Takeshi Nagasaka; Ajay Goel
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

4.  Predominant modifier of extreme liver cancer susceptibility in C57BR/cdJ female mice localized to 6 Mb on chromosome 17.

Authors:  Stephanie E-M Peychal; Andrea Bilger; Henry C Pitot; Norman R Drinkwater
Journal:  Carcinogenesis       Date:  2009-03-02       Impact factor: 4.944

5.  Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy.

Authors:  Naoshi Nishida; Takafumi Nishimura; Toshimi Kaido; Kosuke Minaga; Kentaro Yamao; Ken Kamata; Mamoru Takenaka; Hiroshi Ida; Satoru Hagiwara; Yasunori Minami; Toshiharu Sakurai; Tomohiro Watanabe; Masatoshi Kudo
Journal:  Cancers (Basel)       Date:  2018-09-29       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.